[1] |
Kanda T, Ogasawara S, Chiba T, et al. Current management of patients with hepatocellular carcinoma[J]. World J Hepatol, 2015, 7(15):1913-1920.
|
[2] |
Xiu P, Dong XF, Li XP, et al. Clusterin: review of research progress and looking ahead to direction in hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(27): 8262-8270.
|
[3] |
Oda K, Uto H, Mawatari S, et al. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies[J]. Clin J Gastroenterol, 2015, 8(1):1-9.
|
[4] |
Kikuchi L, Oliveira CP, Carrilho FJ. Nonalcoholic fatty liver disease and hepatocellular carcinoma[J]. Biomed Res Int, 2014: 106247.
|
[5] |
Clarke JD, Novak P, Lake AD, et al. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease[J]. Dig Dis Sci, 2014, 59(2): 365-374.
|
[6] |
Kovacs JJ, Hara MR, Davenport CL, et al. Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways [J]. Dev Cell, 2009, 17(4): 443-458.
|
[7] |
Shenoy SK, Lefkowitz RJ. β-Arrestin-mediated receptor trafficking and signal transduction[J]. Trends Pharmacol Sci, 2011, 32(9): 521-533.
|
[8] |
DeFea KA. Arrestins in actin reorganization and cell migration[J]. Prog Mol Biol Transl Sci, 2013 (118): 205-222.
|
[9] |
Tian X, Kang DS, Benovic JL. β-arrestins and G protein-coupled receptor trafficking[J]. Handb Exp Pharmacol, 2014 (219): 173-186.
|
[10] |
Lundgren K, Tobin NP, Lehn S, et al. Stromal expression of β-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer[J]. J Mol Diagn, 2011, 13(3): 340-351.
|
[11] |
Sobolesky PM, Moussa O. The role of β-arrestins in cancer[J]. Prog Mol Biol Transl Sci, 2013 (118): 395-411.
|
[12] |
Raghuwanshi SK, Smith N, Rivers EJ, et al. G protein-coupled receptor kinase 6 deficiency promotes angiogenesis, tumor progression, and metastasis[J]. J Immunol, 2013, 190(10): 5329-5336.
|
[13] |
Rosanò L, Cianfrocca R, Masi S, et al. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis[J]. Proc Natl Acad Sci U S A, 2009, 106(8): 2806-2811.
|
[14] |
Wang LG, Su BH, Du JJ. Expression of β-arrestin 1 in gastric cardiac adenocarcinoma and its relation with progression[J]. Asian Pac J Cancer Prev, 2012, 13(11): 5671-5675.
|
[15] |
Zhang P, He X, Tan J, et al. β-arrestin2 mediates β-2 adrenergic receptor signaling inducing prostate cancer cell progression[J]. Oncol Rep, 2011, 26(6): 1471-1477.
|
[16] |
Bonnans C, Flacelière M, Grillet F, et al.Essential requirement for β-arrestin2 in mouse intestinal tumors with elevated Wnt signaling[J]. Proc Natl Acad Sci U S A, 2012, 109(8): 3047-3052.
|
[17] |
Kotula JW, Sun J, Li M, et al. Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth[J]. PLoS One, 2014, 9(4): e93441.
|
[18] |
Qiu C, Zheng C, Zhu L, et al. β-arrestin1 over-expression is associated with an unfavorable prognosis in lung adenocarcinomas and correlated with vascular endothelial growth factor[J]. Int J Clin Exp Pathol, 2015, 8(4): 3785-3793.
|
[19] |
Niwa Y, Ishikawa K, Ishigami M, et al. Effect of hyperglycemia on hepatocellular carcinoma development in diabetes[J]. Biochem Biophys Res Commun, 2015, 463(3):344-350.
|
[20] |
Tajima K, Nakamura A, Shirakawa J, et al. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice[J]. Am J Physiol Endocrinol Metab, 2013, 305(8): E987-998.
|
[21] |
Thompson KJ, Swan RZ, Walling TL, et al. Obesity, but not ethanol, promotes tumor incidence and progression in a mouse model of hepatocellular carcinoma in vivo[J]. Surg Endosc, 2013, 27(8):2782-2791.
|